CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

IPO imminent for Phase 1 pharma company Nuvectis

By Andrew Knoll

19:56, 29 November 2021

Doctor discusses care with cancer patient
The company will trade under the ticker NVCT on the Nasdaq - Photo: Shutterstock

Nuvectis, a developer of pretrial targeted treatments for cancer, stands alone on the US IPO docket this week.

The company intends to raise around $30m
 (£22.6m), with shares priced between $12 and $14, to advance its research goals and fund the advancement of two treatments through the clinical trial process. The market capitalisation of the company is estimated at $160m. 

It will trade under the ticker NVCT on the Nasdaq. Its first treatment, the heat shock factor 1 pathway inhibitor NXP800 will enter Phase 1 clinical trials in the fourth quarter of this year.

“We believe that with our two pipeline products, we are now one step closer to creating a diversified precision-medicine oncology-focused company with the goal of helping more people in their fight against hard-to-treat cancers,” Nuvectis CEO Ron Bentsur said.


Nuvectis licensed worldwide rights for NXP800 and a second treatment, NXP900, earlier this year and received $15m (£11.3m) in Series A financing for NXP800. NXP900 is entering trials intended to initiate its investigational new drug phase and explore applications in treating a wide array of cancers manifesting in solid tumours.

“We believe that NXP900’s selectivity and demonstrated potency in several animal models of cancers potentially provide a broad range of development options, both as single agent and in combination with approved drugs,” said Professor Neil Carragher of the University of Edinburgh, where the treatment was initially developed.

NXP800 may also have a broad spectrum of potential uses “such as gastric, hepatocellular, oesophageal, urothelial carcinoma and others,” the company said, though it would initially focus on specific types of ovarian cancer. That tracks with the company’s stated aim of addressing underserved patient markets and filling interstitial medical spaces. For example, there are currently no US Food and Drug Administration-approved medications for endometrioid ovarian carcinoma.

“We plan to initially investigate NXP800 as a treatment for ovarian clear cell cancer and endometrioid ovarian carcinoma,” the Nuvectis prospectus said. “OCCC is highly malignant, difficult to treat, and has a very poor survival rate due to frequent recurrence after surgery and first-line treatment. First-line treatment consists of platinum-based chemotherapy, for which the response rate in relapse/refractory platinum resistant patients is 1%, demonstrating a clear and dire need for a new treatment option for OCCC”.


0.61 Price
-0.060% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 22:00 (UTC)
Spread 0.01168


37,790.75 Price
+0.030% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 106.00


15,931.50 Price
-0.390% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 22:00 (UTC)
Spread 1.8

Oil - Crude

75.81 Price
-2.580% 1D Chg, %
Long position overnight fee -0.0165%
Short position overnight fee -0.0054%
Overnight fee time 22:00 (UTC)
Spread 0.030

Precision-targeted therapy

The global market for precision-targeted therapy like that of Nuvectis was almost $94bn (£71bn) in 2020 and could ascend to about $163bn (£123bn), according to Emergen Research.

Precision-targeted therapies tailor to the genetic makeup of individual patients and the structure of their pathologies, increasing efficacy and durability of results compared with immunotherapy. They tend to focus on genetic aberrations that drive and sustain tumour growth.

With an estimated compound annual growth rate of 7.1%, the sector has attracted significant players. For instance, Eli Lilly partnered with Lycia Therapeutics to collaborate on the development of precision-targeted therapies to serve an aging global population that is facing rising healthcare costs in much of the world.

Read more: AstraZeneca’s Enhertu granted speedier FDA review for breast cancer drug

Related topics

Rate this article

The difference between trading assets and CFDs
The main difference between CFD trading and trading assets, such as commodities and stocks, is that you don’t own the underlying asset when you trade on a CFD.
You can still benefit if the market moves in your favour, or make a loss if it moves against you. However, with traditional trading you enter a contract to exchange the legal ownership of the individual shares or the commodities for money, and you own this until you sell it again.
CFDs are leveraged products, which means that you only need to deposit a percentage of the full value of the CFD trade in order to open a position. But with traditional trading, you buy the assets for the full amount. In the UK, there is no stamp duty on CFD trading, but there is when you buy stocks, for example.
CFDs attract overnight costs to hold the trades (unless you use 1-1 leverage), which makes them more suited to short-term trading opportunities. Stocks and commodities are more normally bought and held for longer. You might also pay a broker commission or fees when buying and selling assets direct and you’d need somewhere to store them safely.
Capital Com is an execution-only service provider. The material provided on this website is for information purposes only and should not be understood as an investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page then you do so entirely on your own risk.

Still looking for a broker you can trust?

Join the 570.000+ traders worldwide that chose to trade with

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading